It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.
Some known poor physicochemical properties that can impact DMPK and/or drug safety include:
- Poor solubility, chemical stability or permeability resulting in reduced GI tract absorption leading to decreased oral bioavailability. This can impact on efficiency or on achieving sufficient high exposures in support of preclinical safety assessment studies.
- High lipophilicity has been linked with high plasma protein binding (and hence potentially reduced tissue penetration), promiscuous binding and off-target toxicity.
We recognise the importance of designing in good physicochemical properties to any lead series. Our computational chemistry group have software packages that predict physicochemical properties and are useful for the design of appropriate hit expansion libraries and during lead optimisation. The profiling of physicochemical properties of compounds from your different chemical series is usually performed within hit to lead or lead optimisation phases of discovery to identify hit clusters with properties to help guide series selection and/or series optimisation.
Our Physico-Chemical Service Offerings
Our robust assays will help you uncover the physicochemical properties of your compounds to help ensure that you have an early understanding of these properties.